1. Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination.
- Author
-
Watson RA, Ye W, Taylor CA, Jungkurth E, Cooper R, Tong O, James T, Shine B, Hofer M, Jenkins D, Pell R, Ieremia E, Jones S, Maldonado-Perez D, Roberts ISD, Coupe N, Middleton MR, Payne MJ, and Fairfax BP
- Subjects
- Aged, Female, Humans, Male, COVID-19 Vaccines adverse effects, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Vaccination adverse effects, Aged, 80 and over, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized therapeutic use, COVID-19 prevention & control, COVID-19 immunology, Myocarditis chemically induced, Myositis chemically induced, SARS-CoV-2 immunology
- Abstract
We describe three cases of critical acute myositis with myocarditis occurring within 22 days of each other at a single institution, all within 1 month of receiving the initial cycle of the anti-PD-1 drug pembrolizumab. Analysis of T cell receptor repertoires from peripheral blood and tissues revealed a high degree of clonal expansion and public clones between cases, with several T cell clones expanded within the skeletal muscle putatively recognizing viral epitopes. All patients had recently received a COVID-19 mRNA booster vaccine prior to treatment and were positive for SARS-CoV2 Spike antibody. In conclusion, we report a series of unusually severe myositis and myocarditis following PD-1 blockade and the COVID-19 mRNA vaccination., Competing Interests: Competing interests: RAW, WY, CAT, EJ, RC, OT, TJ, BS, MH, DJ, RP, EI, SJ, DM-P, NC and MP: no competing interests. MRM reports grants from Roche, grants from Astrazeneca, grants from GSK, other from Novartis, grants and other from Immunocore, other from BMS, other from Pfizer, other from Merck/MSD, other from Regeneron, other from BiolineRx, other from Replimune, grants from GRAIL; all outside the submitted work; ISDR reports consultancy for Novartis, Travere Therapeutics, Q32Bio and is an unpaid Director of Oxford Pathology Education Limited, Oramis Digital Autopsy, UK Renal Pathology; all outside submitted work. BF has received speaker fees from GSK, Immunocore, BMS and reports consultancy for Roche, Pathios Therapeutics, NICE advisory, UCB; NC has received honoraria Pierre Fabre, BMS., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF